Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
Home
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)
Next Post
Previous Post
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience Announces Preliminary Data for FYARROâ„¢ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Phase 2 study of
nab
-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Read More
Stephen Rodin, JD
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009)
Long-term follow-up for duration of response (DOR) after weekly
nab
-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.